Haematology

News

Is GSK’s Blenrep heading for a renaissance?

A year after GSK pulled its BCMA-targeting antibody-drug conjugate (ADC) Blenrep from the US market as a later-line therapy for multiple myeloma, there are signs that the

News

MorphoSys shrugs off mixed results for myelofibrosis drug

MorphoSys has said it will press ahead with regulatory filings for its myelofibrosis drug candidate pelabresib, despite mixed results in a phase 3 trial.

News

CHMP backs GSK’s momelotinib for myelofibrosis

GSK is on the brink of EU approval for JAK inhibitor momelotinib as a treatment for myelofibrosis patients with anaemia, after the EMA’s human medicines committee issued a

News

Takeda gets okay in US for rare blood disorder drug

Patients in the US with ultra-rare blood clotting disorder congenital thrombotic thrombocytopenic purpura (cTTP) have an FDA-approved therapy for the first time, after Tak

News

Faron’s Clever-1 drug shows promise in blood cancers

Faron Pharmaceuticals has reported data from a phase 1/2 trial pointing to the potential of its macrophage-directed antibody bexmarilimab as a treatment for blood cancers

News

FDA starts swift review of Regeneron’s CD20 bispecific

The FDA has started a priority review of Regeneron’s CD20xCD3 bispecific antibody odronextamab, seeking a broader label than other drugs in the class.

Is GSK’s Blenrep heading for a renaissance?

MorphoSys shrugs off mixed results for myelofibrosis drug

CHMP backs GSK’s momelotinib for myelofibrosis

Takeda gets okay in US for rare blood disorder drug

Faron’s Clever-1 drug shows promise in blood cancers

FDA starts swift review of Regeneron’s CD20 bispecific

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Haematology

Editor's Picks